ESMO Media Releases

ESMO, the leading professional organisation for medical oncology, is pleased to announce the ESMO Asia 2017 Congress, which will be held 17 to 19 November at the Suntec Singapore Convention and Exhibition Centre.

ESMO President, Fortunato Ciardiello, has contributed an editorial on the priorities for future cancer research, to The Lancet Oncology with Josep Tabernero, ESMO President-Elect as co-author.

ESMO, the leading European professional organisation for medical oncology, was present at the WHO Global Conference on Noncommunicable Diseases (NCDs*) that finished last Friday in Montevideo, Uruguay.

Men who smoke and have five or more partners with whom they perform oral sex have the highest risk of developing a type of head and neck cancer that is triggered by exposure to the human papilloma virus – known as HPV-related oropharyngeal cancer – according to research published in the leading cancer journal Annals of Oncology [1] today (Friday).

Cancer outcome depends on complex interactions between many mutations, experts highlighted at the Molecular Analysis for Personalised therapy (MAP) Congress, held 13-14 October in Zurich, Switzerland.

ESMO has granted the newly established ESMO Award in Immuno-Oncology to honour individuals for their outstanding achievements in the field.

ESMO, the leading European professional organisation for medical oncology announced today that Professor Fabrice André, MD, PhD, will be the new interim Editor-in-Chief of Annals of Oncology as of 14 September 2017.

ESMO 2017 was a truly global event with nearly 24,000 participants from 131 countries. The ten countries with the most delegates were the USA, France, Spain, UK, Germany, Italy, Switzerland, China, Japan, and Russia.

Randomised controlled trials with positive results are twice as likely to be reported by the lay press as those with negative trials, according to results from the Best Poster in Public Health and Health Economics at the ESMO 2017 Congress in Madrid.

Adjuvant nivolumab is superior to standard of care ipilimumab in patients with surgically resected stage III/IV melanoma who are at high risk of relapse, according to late-breaking results from the CheckMate 238 trial presented today at the ESMO 2017 Congress in Madrid (1) and published in the New England Journal of Medicine (NEJM).

Combination targeted adjuvant therapy with dabrafenib and trametinib doubles relapse-free survival in patients with stage III BRAF-mutant melanoma, according to late-breaking results from the COMBI-AD trial presented today at the ESMO 2017 Congress in Madrid (1) and published in the New England Journal of Medicine.

The debate on whether to shorten adjuvant chemotherapy for colon cancer from six to three months takes centre stage today in a special session at the ESMO 2017 Congress in Madrid.